{
  "docId": "019de075-0704-766b-8dc2-5164487e52e7",
  "docSlug": "289762853c89269e6344134613f84a84",
  "documentTitle": "OmniAb | Investor Presentation Deck | 39 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 39,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-0704-766b-8dc2-5164487e52e7/10",
  "deckHref": "/decks/019de075-0704-766b-8dc2-5164487e52e7",
  "deckJsonHref": "/decks/019de075-0704-766b-8dc2-5164487e52e7.json",
  "deckAnchorHref": "/decks/019de075-0704-766b-8dc2-5164487e52e7#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.66,
        "y": 0.43
      },
      "kind": "list",
      "text": "SGN-BB228: Investigational costimulatory bispecific molecule; Seagen announced Phase 1 study now enrolling in advanced melanoma and other solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8304fcf0-6ab0-4b2a-8216-240aac5c6609",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.1,
        "y": 0.43
      },
      "kind": "list",
      "text": "Batoclimab: Ongoing studies in Myasthenia Gravis (P3), Thyroid Eye Disease (P3), Chronic Inflammatory Demyelinating Polyneuropathy (P2b), Graves' Disease (P2)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b7214ff-0a31-4b20-8bda-1e957ecd8da3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.38,
        "y": 0.43
      },
      "kind": "list",
      "text": "IMVT-1402: Next-gen FcRn antagonist; Immunovant expects SAD/MAD Phase 1 data in second half of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5bdc228-d01c-4137-a3a8-a31972c3da2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Reference: Partner and Company disclosures",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea95a0b9-7e95-4744-bbcb-99cdd91f7e71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "SELECT RECENT DEVELOPMENTS SHOW CONTINUED PARTNER MOMENTUM",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3d9f26d-2328-4645-8d51-f11544ecabf6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Q1 2023 and Recent Updates",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e91ee6c3-3d24-4465-8d63-0df6c8fb8694",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 6,
      "beatId": "3c747586-5f51-405c-b39c-0f663acb5a84",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Interest",
      "beatSlug": "aida-interest",
      "evidence": "The deck presents the company's solution, technology offering, and traction to generate interest.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c9464b73-5d72-4cd7-a643-34a139bcb87a",
      "evidence": "The deck presents the need for discovery technology and the limitations of current solutions.",
      "position": 0,
      "objective": "What are the consequences of not investing in OmniAb's platform?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}